Barinthus Biotherapeutics plc.
BRNS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BRNS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BRNS
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic product candidates for infectious diseases and cancer, with a lead program (VTP-300) in Phase 2 and a cash position of $59.6M as of June 30, 2026.
Key risk: Clinical trial risks
BioSniper Score
Based on 5 of 6 signals
Market Cap
$30.5M
Cash Runway
22.5 moLead Asset
VTP-1000 (Early Phase 1)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials · 1 catalyst for Barinthus Biotherapeutics plc..
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic product candidates for infectious diseases and cancer, with a lead program (VTP-300) in Phase 2 and a cash position of $59.6M as of June 30, 2026.
- Barinthus Biotherapeutics has an accumulated deficit of $320.2 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company reported cash, cash equivalents and restricted cash of $59.6 million [sec_mda · as of 2026-08-06].
- The company expects to continue to incur significant losses and negative cash flows from operations for the foreseeable future [sec_mda · as of 2026-08-06].
- Barinthus has raised gross proceeds of approximately $330.1 million from the issuance of ordinary and preferred shares and convertible loan notes [sec_mda · as of 2026-08-06].
- The company's lead product candidate, VTP-300, is in Phase 2 development, with a topline readout expected by December 31, 2026 [upcoming catalysts].
What works
- The company has raised substantial capital, with gross proceeds of approximately $330.1 million from equity and convertible debt [sec_mda · as of 2026-08-06].
- Barinthus has a defined catalyst with a Phase 2 topline readout for VTP-300 expected by the end of 2026 [upcoming catalysts].
What to weigh
- The company has a significant accumulated deficit of $320.2 million as of June 30, 2026, with no expectation of near-term profitability [sec_mda · as of 2026-08-06].
- Barinthus expects to continue incurring substantial losses and negative cash flows, and its cash runway is limited by ongoing development costs [sec_mda · as of 2026-08-06].
- The company faces numerous risks including successful completion of clinical trials, regulatory approval, and commercial acceptance of any product candidates [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Accumulated deficit as of June 30, 2026
“June 30, 2026 and as of June 30, 2026, we had an accumulated deficit of $320.2 million.”
SEC MD&A · August 6, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash, cash equivalents and restricted cash of $59.6 million.”
SEC MD&A · August 6, 2026
Expectation of continued losses
“We expect to continue to incur significant losses and negative cash flows from operations for the foreseeable future.”
SEC MD&A · August 6, 2026
Gross proceeds raised
“gross proceeds of approximately $330.1 million from the issuance of our ordinary and preferred shares and convertible loan notes.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · vtp-300 — Phase 2 Readout: vtp-300 — Topline data from the Phase 2 trial of VTP-300 is expected, which will inform the program's efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- Clinical trial risks — Successful completion of preclinical studies and clinical trials is uncertain, and delays or failures could materially impact the company [sec_mda · as of 2026-08-06].
- Regulatory and approval risks — The company may not obtain marketing authorizations for product candidates that complete clinical trials [sec_mda · as of 2026-08-06].
- Commercialization risks — Even if approved, product candidates may not achieve market acceptance or adequate reimbursement from payors [sec_mda · as of 2026-08-06].
- Financial sustainability — The company has a large accumulated deficit and expects continued negative cash flows, raising going-concern risks [sec_mda · as of 2026-08-06].
What to watch
- Phase 2 topline readout for VTP-300 expected by December 31, 2026 [upcoming catalysts].
- Cash burn rate and any additional financing activities, given the $59.6M cash position as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Updates on clinical trial enrollment and data for other pipeline candidates [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Barinthus Biotherapeutics plc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Barinthus Biotherapeutics plc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
22.5 months
D/E 0.43 · 0% dilution
Lead: Early Phase 1
1 candidate
1 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$6.1M
| Holder | Shares | Value |
|---|---|---|
| m&g plc | 5,197,349 | $5.2M |
| glr partners, llc | 1,243,377 | $707K |
| renaissance technologies llc | 151,000 | $86K |
| citadel advisors llc | 118,996 | $68K |
| gts securities llc | 73,210 | $42K |
| hightower advisors, llc | 37,450 | $21K |
| rhumbline advisers | 11,685 | $7K |
| geode capital management, llc | 11,568 | $7K |
| morgan stanley | 2,210 | $1K |
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 8,236
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BRNS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Barinthus Biotherapeutics plc.?
Barinthus Biotherapeutics plc (BRNS) is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic product candidates for infectious diseases and cancer, with a lead program (VTP-300) in Phase 2 and a cash position of $59.6M as of June 30, 2026.
What is Barinthus Biotherapeutics plc.'s lead drug candidate?
Barinthus Biotherapeutics plc.'s most advanced tracked candidate is VTP-1000 (Early Phase 1) for Celiac Disease.
What is Barinthus Biotherapeutics plc.'s next catalyst?
Barinthus Biotherapeutics plc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: vtp-300" — expected December 31, 2026.
Who is the CEO of Barinthus Biotherapeutics plc.?
Mr. William James Enright MBA is the chief executive officer of Barinthus Biotherapeutics plc. (BRNS).
Where is Barinthus Biotherapeutics plc. headquartered?
Barinthus Biotherapeutics plc. (BRNS) is headquartered in Germantown, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.